Table 3 Summary of PWID intravenous drug use stratified by endocarditis history
From: Risk factors of infective endocarditis in persons who inject drugs
Variable (%) | Control (n = 102; %) | Case (n = 33; %) | p value |
|---|---|---|---|
Drug injected | |||
 Oxycodone hydrochloride tablets (Oxycontin) | 43 (42.2) | 10 (30.3) | 0.22 |
 Hydromorphone controlled-release capsules (Hydromorph contin) | 83 (81.4) | 30 (90.9) | 0.20 |
 Crystal methamphetamine | 80 (78.4) | 18 (54.5) | 0.07 |
 Hydromorphone controlled-release tablets (Dilaudid) | 76 (74.5) | 21 (63.6) | 0.23 |
 Bupropion (Wellbutrin) | 0 (0) | 1 (3) | 0.24 |
 Methylphenidate (Ritalin) | 18 (17.6) | 4 (12.1) | 0.60 |
 Cocaine | 16 (15.7) | 3 (9.1) | 0.41 |
 Crack | 8 (7.8) | 0 | 0.20 |
 Fentanyl patch | 1 (1.0) | 3 (9.1) | 0.45 |
 Fentanyl tablet | 4 (3.9) | 1 (3.0) | 1.00 |
 Heroin | 14 (13.7) | 4 (12.1) | 1.00 |
Injection location most frequently used | Â | Â | 0.012a |
 Arm | 62 (64.6) | 12 (48.0) |  |
 Hand | 3 (3.1) | 2 (8.0) |  |
 Neck | 12 (12.5) | 2 (8.0) |  |
 Leg* | 6 (6.2) | 1 (4.0) |  |
 Foot | 1 (1.0) | 0 (0.0) |  |
 Multiple sites** | 12 (12.5) | 8 (32.0) |  |
Injection location used in the past 3 months |  |  | 0.38a |
 Hand*** | 13 (14.8) | 1 (3.4) |  |
 Lower leg | 1 (1.1) | 1 (3.4) |  |
 Feet | 1 (1.1) | 0 (0.0) |  |
 Neck | 8 (9.1) | 3 (10.3) |  |
 Multiple sites** | 65 (73.9) | 24 (82.8) |  |